Abdulrhman Khaity, Khaled Albakri, Nada Mostafa Al-Dardery, Yaman A S Yousef, Jose A Foppiani, Samuel J Lin
{"title":"脂肪来源干细胞治疗增生性瘢痕和瘢痕疙瘩:实验研究的系统回顾","authors":"Abdulrhman Khaity, Khaled Albakri, Nada Mostafa Al-Dardery, Yaman A S Yousef, Jose A Foppiani, Samuel J Lin","doi":"10.1177/22925503231195017","DOIUrl":null,"url":null,"abstract":"<p><p><b>Introduction:</b> Hypertrophic and keloid scars are abnormal tissue growth that can be disfiguring, for which the available treatment has not yielded consistent results. Therefore, this study aimed to evaluate the capability of Adipose tissue-derived stem cell (ADSC) therapy in treating these scars. <b>Methods:</b> A literature search was conducted on PubMed, Scopus, Cochrane Library, and Web of Science from inception until July 2022. We included experimental studies that evaluated ADSCs as a therapy for hypertrophic and keloid scars in both in-vivo and in-vitro models. <b>Results:</b> Our findings extracted from 12 included studies demonstrated that ADSCs have a promising potential in reducing collagen deposition, proliferation, and migration rates of fibroblast, decreasing gene/protein expression of scar-related molecules including levels of TGF-β1 and lowering intracellular signal pathway-related molecules of hypertrophic and keloid scars in both models. However, no significant difference (<i>P</i> > .05) was found in the hypertrophic scar in-vitro models in terms of DCN gene expression. <b>Conclusion:</b> Ultimately, the current studies included in this systematic review support the use of ADSCs to alleviate hypertrophic and keloid scars.</p>","PeriodicalId":20206,"journal":{"name":"Plastic surgery","volume":" ","pages":"318-328"},"PeriodicalIF":0.7000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059430/pdf/","citationCount":"0","resultStr":"{\"title\":\"Adipose-Derived Stem Cell Therapy in Hypertrophic and Keloid Scars: A Systematic Review of Experimental Studies.\",\"authors\":\"Abdulrhman Khaity, Khaled Albakri, Nada Mostafa Al-Dardery, Yaman A S Yousef, Jose A Foppiani, Samuel J Lin\",\"doi\":\"10.1177/22925503231195017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Introduction:</b> Hypertrophic and keloid scars are abnormal tissue growth that can be disfiguring, for which the available treatment has not yielded consistent results. Therefore, this study aimed to evaluate the capability of Adipose tissue-derived stem cell (ADSC) therapy in treating these scars. <b>Methods:</b> A literature search was conducted on PubMed, Scopus, Cochrane Library, and Web of Science from inception until July 2022. We included experimental studies that evaluated ADSCs as a therapy for hypertrophic and keloid scars in both in-vivo and in-vitro models. <b>Results:</b> Our findings extracted from 12 included studies demonstrated that ADSCs have a promising potential in reducing collagen deposition, proliferation, and migration rates of fibroblast, decreasing gene/protein expression of scar-related molecules including levels of TGF-β1 and lowering intracellular signal pathway-related molecules of hypertrophic and keloid scars in both models. However, no significant difference (<i>P</i> > .05) was found in the hypertrophic scar in-vitro models in terms of DCN gene expression. <b>Conclusion:</b> Ultimately, the current studies included in this systematic review support the use of ADSCs to alleviate hypertrophic and keloid scars.</p>\",\"PeriodicalId\":20206,\"journal\":{\"name\":\"Plastic surgery\",\"volume\":\" \",\"pages\":\"318-328\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059430/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Plastic surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/22925503231195017\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/8/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Plastic surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/22925503231195017","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/21 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
摘要
简介:肥厚性瘢痕和瘢痕疙瘩是一种异常的组织生长,可以毁容,对于可用的治疗尚未产生一致的结果。因此,本研究旨在评估脂肪组织源性干细胞(ADSC)治疗这些疤痕的能力。方法:检索PubMed、Scopus、Cochrane Library和Web of Science自成立至2022年7月的文献。我们纳入了在体内和体外模型中评估ADSCs作为肥厚性疤痕和瘢痕疙瘩治疗方法的实验研究。结果:我们从12项纳入的研究中提取的结果表明,在两种模型中,ADSCs具有降低成纤维细胞胶原沉积、增殖和迁移率,降低TGF-β1等疤痕相关分子的基因/蛋白表达,降低增生性瘢痕和瘢痕疙瘩疤痕的细胞内信号通路相关分子的潜力。而增生性瘢痕体外模型DCN基因表达差异无统计学意义(P < 0.05)。结论:最终,本系统综述中包括的当前研究支持使用ADSCs减轻肥厚性瘢痕和瘢痕疙瘩。
Adipose-Derived Stem Cell Therapy in Hypertrophic and Keloid Scars: A Systematic Review of Experimental Studies.
Introduction: Hypertrophic and keloid scars are abnormal tissue growth that can be disfiguring, for which the available treatment has not yielded consistent results. Therefore, this study aimed to evaluate the capability of Adipose tissue-derived stem cell (ADSC) therapy in treating these scars. Methods: A literature search was conducted on PubMed, Scopus, Cochrane Library, and Web of Science from inception until July 2022. We included experimental studies that evaluated ADSCs as a therapy for hypertrophic and keloid scars in both in-vivo and in-vitro models. Results: Our findings extracted from 12 included studies demonstrated that ADSCs have a promising potential in reducing collagen deposition, proliferation, and migration rates of fibroblast, decreasing gene/protein expression of scar-related molecules including levels of TGF-β1 and lowering intracellular signal pathway-related molecules of hypertrophic and keloid scars in both models. However, no significant difference (P > .05) was found in the hypertrophic scar in-vitro models in terms of DCN gene expression. Conclusion: Ultimately, the current studies included in this systematic review support the use of ADSCs to alleviate hypertrophic and keloid scars.
期刊介绍:
Plastic Surgery (Chirurgie Plastique) is the official journal of the Canadian Society of Plastic Surgeons, the Canadian Society for Aesthetic Plastic Surgery, Group for the Advancement of Microsurgery, and the Canadian Society for Surgery of the Hand. It serves as a major venue for Canadian research, society guidelines, and continuing medical education.